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An enhanced and sensitive autocrine stimulation by transforming growth
factor-ac is acquired in the brain metastatic variant of a human non-small-
cell lung cancer cell line
K Fang
Department ofBiology, National Taiwan Normal University, Taipei 11718, Taiwan, Republic of China.
Summary Transforming growth factor-a (TGF-oa)-mediated autocrine regulation in human non-small-cell lung
cancer (NSCLC) cells NCI-H226 and its brain metastatic variant H226Br were compared. An enhanced TGF-
cx-induced dose-dependent mitogenic responsiveness in H226Br cells was observed. Neutralising antibody that
binds TGF-a inhibits H226Br cell growth more effectively than NCI-H226 cell growth. Binding assay with 12511
labelled epidermal growth factor (EGF) revealed that H226Br has two types of EGF receptors (EGFRs),
whereas the parental cell line, NCI-H226, has only one. H226Br cells contain twice as many EGFRs as H226
cells, as proved by Scatchard analysis and immune kinase assay. Northern analysis indicated that there is more
EGFR transcript in H226Br than in NCI-H226, indicating a transcriptional EGFR gene elevation during
metastasis progression. The level of accumulated immunoactive TGF-a is lower in the conditioned medium of
H226Br than in that ofNCI-H226, demonstrating down-regulation of TGF-cc transcript. The accumulated data
suggest an elevated and sensitive autocrine modulation by TGF-a and EGFR in immortalising the brain
metastatic variant cells that were derived from a human NSCLC squamous cell line.
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Regulation of cell growth factors and the production of
receptors that lead to different autocrine stimulation is a
common phenomenon in many tumour cell types (Browder et
al., 1989). Epidermal growth factor receptor (EGFR) is
expressed in human lung cancer cell lines (Haeder et al.,
1988). Human EGFR is a single-chain transmembrane
glycoprotein with intrinsic tyrosine-protein kinase activity
(Carpenter, 1987; Carpenter et al., 1979; Hunter and Cooper,
1979) that is stimulated by EGF or EGF-like factors (Ullrich
and Schlessinger, 1990; MacDonald et al., 1990). EGFR is
responsible for the mediation of proliferative responses in
many tumour cells and tissues (Fitzpatrick et al., 1984; Xu et
al., 1984). Elevated expression or activity of EGFR has been
reported in normal human keratinocytes (Coffey et al., 1987)
and neoplasms of the human prostate (Gelman, 1991),
bladder (Smith et al., 1989), breast (Ro et al., 1988) and
head and neck (Ishitoya et al., 1989) as well as in brain
(Liberman 1984), kidney (Petrides et al., 1990) and colon
carcinoma cells (Untawale et al., 1993), transformed
mammary epithelium (Valverius et al., 1989), and mesothe-
lium (Bermudez et al., 1990).
Transforming growth factor-cc (TGF-a) is a 50 amino acid
polypeptide that belongs to the epidermal growth factor
family (Massaugue and Pandiella, 1993) and binds to EGFR
with a high affinity. It activates cell growth by tyrosine
phosphorylation of EGFR. Thus, the increased EGFR
activity in tumorigenesis is attributed to autocrine stimula-
tion by TGF-a (Di Marco et al., 1989), which is produced by
a variety of retrovirus-, chemical- and oncogene-transformed
human and rodent cell lines (Coffey et al., 1992; Aaronson,
1993). TGF-ac competes with EGF for binding to EGFR
because of their structural similarity (Todaro and DeLarco,
1976; Todaro et al., 1980). According to the autocrine
hypothesis, the TGF-a produced by transformed cells acts on
the cell-surface EGFR to promote unstained cell proliferation
(Salomon et al., 1990; Sporn and Roberts, 1985). Increases in
EGFR levels have also been caused by gene amplification
(King et al., 1985), enhanced transcription (Downward et al.,
1984) and a decreased metabolic turnover rate (Gamou and
Shimiyu, 1987). Expression of EGFR and TGF-a in human
non-small-cell lung cancer (NSCLC) has been reported
(Rabiasz et al., 1992; Rusch et al., 1993), but very few
detailed studies on TGF-cx activity in NSCLC cells have been
reported.
In this study, the molecular mechanisms for TGF-a-
regulated autocrine activity of NSCLC cells and their
metastatic variants were investigated. Squamous cell
carcinoma cells are known for their brain metastasis
potential (Schackert et al., 1989; Fidler and Schackert,
1991). The cell line used in this report, H226Br, was derived
by intracarotid injection of human NSCLC cells NCI-H226
into athymic BALB/c mice and selected from the developed
brain tumour (Hwang et al., 1995). An enhanced TGF-a-
mediated mitogenic response in H226Br cells was observed.
The role of EGFR and the TGF-ac ligand of both cultured
cell lines was compared. We found that EGFR expression of
H226Br cells is elevated to varying extents, whereas ligand
TGF-a expression is decreased compared with the parental
cells NCI-H226. The cell growth of H226Br is inhibited in a
dose-dependent manner by TGF-cx-specific antibody, indicat-
ing the acquisition of effective TGF-cx-mediated autocrine
regulation during brain metastasis progression of human
NSCLC cells.
Materials and methods
Cell lines
Human lung squamous cell carcinoma cell lines NCI-H226,
NCI-H460 and NCI-H322 were obtained from Dr A Gazdar
(Southwestern Medical Centre, Dallas, TX, USA). The cells
were grown in RPMI-1640 (Gibco-BRL, Grand Island, NY,
USA) medium supplemented with L-glutamine, sodium
pyruvate and 5% heat-inactivated fetal calf serum (Intergen,
Purchase, NY, USA) in a humidified atmosphere of 5%
carbon dioxide. Cell line H226Br was developed by Dr IJ
Fidler and was cultured in RPMI-1640 supplemented with 5%
heat-inactivated fetal calf serum. The cells were examined and
found to be free of mycoplasma contamination.
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Receptor-grade EGF (Collaborative Research, Boston, MA,
USA) was labelled with carrier-free Na'25I (Amersham) using
the chloramine-T method (Carpenter and Cohen, 1976). Cells
(5 x 105 per well) were cultured in six-well plates and allowed
to attach overnight. The medium was aspirated and replaced
with serum-free medium after 3 h incubation. After
determination of cell numbers per well, the cells were
washed twice with ice-cold phosphate-buffered saline (PBS)
supplemented with 0.2% bovine serum albumin (BSA).
Various concentrations of 1251-labelled EGF were added to
each well. After 2 h incubation at 4°C, the cells were washed
in ice-cold PBS three times, and the bound radioactivity was
determined after the cells were lysed in a 50 mM sodium
hydroxide and 10% sodium dodecyl sulphate (SDS) mixture.
The non-specific binding was determined and contained a
100-fold molar excess of native EGF. Calculation of binding
sites and the dissociation constant, Kd, were determined by
Scatchard analysis (Scatchard, 1949). The human epidermoid
cancer cell line A431 was used as a positive control.
Cell growth proliferation assay
Cells were first cultured in 96-well microtitre plates in RPMI-
1640 medium supplemented with 5% fetal calf serum
overnight. The medium was changed to 200 ,ul of serum-
free RPMI-1640 containing insulin (5 pl ml-1), transferrin
(10 pg ml-') and sodium selenite (30 pg ml-1) (Avis et al.,
1995; Brower et al., 1986) overnight. After 24 h incubation at
37°C with various concentrations of TGF-ax in quadruplicate,
the assay was added 20 pl of 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) (5 mg ml-1; Sigma, St
Louis, MO, USA) dissolved in phosphate-buffered saline
(PBS) for 4 h. Acid isopropanol (100 pl of 0.04 N hydro-
chloric acid in isopropanol) was added and mixed thoroughly
to dissolve the formazam crystals. The plate was read on a
microplate reader, using a 570 nm wavelength while a 630 nm
reading was set as the reference (Mosman, 1988). Readings
from cell cultures that were not treated with growth factors
were used as controls. Statistical significance were determined
using the two-tailed Student's t-test.
Neutralisation assay
Cells were seeded into 96-well microtitre plates at a density of
1 x 104 cells per well in 200 pl of growth medium and
cultured for 24 h. The cells were rinsed with PBS and the
medium changed to 200 pl of serum-free RPMI-1640 medium
supplemented with insulin (5 pl ml-'), transferrin
(10 pg ml-') and sodium selenite (30 pg ml-'). After a
further 24 h incubation at 37°C with either various
concentrations of TGF-a monoclonal antibody (Oncogene
Science) or non-specific antibody MOPC-21 (Organon
Teknika-Cappel, Durham, NC, USA) in quadruplicate,
20 pl of MTT (5 mg ml-') was added, and the reading was
taken, as previously described, using a growth proliferation
assay.
Immune complex kinase assay for EGFR
Kinase assay was performed as previously described with
modification (Maxwell et al., 1989). Cells from 75% confluent
flasks were lysed and Dounce homogenised in RIPA lysis
buffer [1% Triton X-100, 150 mm sodium chloride, 5 mM
EDTA, 1% aprotonin, 5 mM phenylmethylsulphonyl fluoride
(PMSF), 10 pg ml-' leupeptin and 20 mM sodium phosphate,
pH 7.0]. Five hundred micrograms of clarified cell lysates was
incubated for 1 h with 5 pl of a monoclonal antibody against
the EGFR extracellular domain R, (Amersham, Arlington
Heights, IL, USA). Immune complexes were harvested by
addition of Staphylococcus aureus (Cowan strain) (Calbio-
chem, La Jolla, CA, USA) for 30 min. The buffer containing
10 pl of [y-32P]ATP (3000 Ci mmol-'), 6 mM manganese
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chloride, 20 mM Hepes (pH 7.0) and 10 ,UM sodium
orthophosphate was added. Phosphorylated proteins were
resolved by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE, 7.5% resolving gels). The gels
were washed in 1 N sodium hydroxide at 80°C for 1 h and
dried. The dried gels were exposed to Kodak X-Omat film
before development.
Biosynthetic labelling and phosphorylation of EGFR in intact
cells
Cells were cultured at I x 106 cells per 60 mm dish 12 -16 h
before labelling. The growth medium was removed, and cells
were incubated for 4 h in 1 ml ofmethionine-free RPMI-1640
medium containing 10% dialysed fetal calf serum and 80 ,Ci
of [35S]methionine (1100 Ci mmol-1; ICN Biomedicals, Costa
Mesa, CA, USA). To study phosphorylation in intact cells,
the cells were stimulated with 200 ng ml-' EGF for 20 min at
37C. The cells were washed with PBS and extracted with a
mixture of 50 mm sodium N-2-hydroxyethylpiperazine-N'-2-
ethanesulphonate (pH 7.5), 150 mm sodium chloride, 1 mM
ethyleneglycol -bis-(,B-aminoethylether)-N,N,N',N'-tetraacetic
acid, 1.5 mM magnesium chloride, 10% glycerol, 1% Triton-
X, 4 ,ug ml-' PMSF, 10 ,ug ml-' leupeptin, 10 jg ml-'
aprotinin, 100 mM sodium chloride, 10 mM sodium pyropho-
sphate, 30 mM p-nitrophenyl phosphate and 200 uM sodium
orthovanadate. EGFR-specific R, antibody (5 ,l), or
antiphosphotyrosine antibody-agarose conjugate (Oncogene
Science) (25 ,l), or non-specific antibody MOPC-21 (5 ul)
was added to cell lysate, followed by 1.5 h incubation. Fifty
microlitres of Staphyloccous aureus was added for 1.5 h at
ice-cold temperature. After washing, cell pellets were
extracted with SDS-PAGE sample buffer, heated to 100°C
for 3 min and applied to vertical slab gels. For fluorography,
gels were treated with Enlighting (New England Nuclear-
Dupont) before drying. Dried gels were exposed to Kodak X-
Omat film at -70°C before development.
Northern blot analysis of EGFR gene expression
Total RNA from more than 60% confluent cell lines was
extracted by guanidinium isocyanate according to published
procedures (Chomczynski and Sacchi, 1987). Poly(A+)RNA
was purified by oligo(dT)cellulose-affinity chromatography
(Collaborative Research, Bedford, MA, USA) following the
protocols. Twenty micrograms of poly(A+) RNA was
separated on a 1.2% formaldehyde-denatured agarose gel in
20 mM 3-(N-morpholino)-propanesulphonic acid buffer (pH
7.0) and blotted onto GeneScreen membranes (New England
Nuclear, Boston, MA, USA). For hybridisation, the cDNA
probe 64-1, containing an 1.8 kb EcoRI fragment of the
extracellular region of EGFR was used (Hung et al., 1986).
The probe was labelled with [c_-32P]dCTP using the Random
Multiprime Labelling System (Amersham). The hybridisation
was carried out at 42°C in 50% deionised formamide, 0.2%
polyvinylpyrrolidone, 0.2% Ficoll, 0.2% BSA, 0.1% sodium
pyrophosphate, 50 mM Tris HCl (pH 7.5), 1 M sodium
chloride, 10% dextran sulphate, 1% SDS and 100 pg ml-'
denatured salmon sperm DNA at 2 x 107 c.p.m. specific
activity for 18 h. Blots were washed in 2 x SSC
(1 x SSC =0.15 M sodium chloride, 15 mM sodium citrate,
pH 7.0) and 1% SDS at 65°C for 1 h, followed by 0.1 x SSC
at room temperature for 1 h. Membranes were reprobed with
a 1.8 kb BamHI fragment of the human ,B-actin cDNA clone
pHFl to eliminate the loading difference between samples.
Reverse transcriptase polymerase chain reaction and Southern
analysis of TGF-a
Total RNA was reverse transcribed with M-MLV reverse-
transcriptase (Promega, Madison, WI, USA) in the presence
of 30 U RNAse inhibitor, 10 pg ml of random primer
(Promega, Madison, WI, USA) and 1 mM dNTP mixture.
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primers encompassing nt 35-216 ofTGF-a cDNA and 0.5 U
of Taq polymerase (Gibco-BRL, Gaithersburg, MD, USA)
using an automatic thermal cycler. A 35-cycle polymerase
chain reaction that included 95°C denaturation for 1 min,
45°C annealing for 1 min and 72°C extension for 2 min was
performed. The amplified cDNA was separated, eluted and
cloned into pGEM-T vector (Promega, Madison, WI, USA).
The cloned TGF-oc cDNA fragment was confirmed by
sequencing and digested from the construct for digoxigenin
labelling (BMB, Mannheim, Germany).
A 297 bp DNA fragment covering TGF-oe cDNA nt 35-
331 in exons 1, 2, 3 and 4 (sense primer, 5'-
ATGGTCCCCTCGGCTGGACA-3'; and antisense primer
5'-GGCCTGCTTCTTCTTCTGGCTGGC-3') (Valverius et
al., 1989) were separated in ethidium bromide-stained 0.8%
agarose gel. The gel was transferred to nylon paper and the
blot hybridised with digoxigenin-labelled 182 bp probe for
TGF-a. The blot was washed and detected with anti-
digoxigenin-alkaline phosphatase conjugate and visualised
with Lumigen PPD chemiluminescent detection reagents
(BMB, Mannheim, Germany) and exposed to radiographic
film. A 420 bp fragment for ,B-actin (sense primer, 5'-
GACTTCGAGCAGGAGATGGCCA-C-3'; and antisense
primer, 5'-CTCCTGCTTGCTGATCCACATC-3') (Barral-
Netto et al., 1992) was amplified and detected with the
1.8 kb BamHI fragment of the human JJ-actin cDNA clone
pHF1.
Determination ofsecreted immunoactive TGF-oa in conditioned
medium
Cell-secreted TGF-a in the conditioned medium was
measured by RIA according to the published procedure
(Walker et al., 1995). The cells were cultured in serum-free
medium for 24 h, and the collected medium centrifuged to
remove the non-adherent cells, followed by addition of 1 mM
PMSF to inhibit protease activity, and concentrated by
Centricon-3 concentrator (Amicon, Beverly, MA, USA). The
immunoactive TGF-ax was assayed using anti-human TGF-a
polyclonal antibody (Peninsula Laboratories, Belmont, CA,
USA). The tracer '25I-labelled human TGF-a was labelled
with Iodobeads (Pierce, St Louis, MO, USA; 120 1Ci ig-'
labelled TGF-ax). Dose response curves were performed in
competition with tracer TGF-oa.
Results
Different EGFR-binding characteristics of H226Br cells
EGF binding sites of both cell lines were determined by 1251_
labelled EGF. Scatchard analysis indicated that the parental
cell line, NCI-H226, has one type of EGF binding site
(4.5 x 104 per cell) with a dissociation constant, Kd, of
12.5 nM. In contrast, the brain metastatic variant H226Br
has two types of receptors: 6.9 x 104 low-affinity receptors per
cell with a Kd of 12 nM and 2.26 x 104 high-affinity receptors
per cell with a Kd of 0.76 nM (Figure 1). The maximum cell-
bound radioactivity in H226Br is more than that of the
parental cells (Figure 1, inset).
Enhanced TGF-cx sensitivity in H226Br cells
The presence of EGFR in cell suggests that TGF-a may act
as autocrine regulator for both cell lines. To determine the
effect of TGF-a on the growth of NCI-H226, NCI-H322,
NCI-H460 and H226Br, 1 x 104 cells were incubated in
serum-free medium before addition of growth factors. After
stimulation with 10 ng ml-' TGF-a for 24 h, the growth of
NCI-H226, NCI-H322 and NCI-H460 was increased by 24%,
26% and 12% respectively, whereas same numbers of
H226Br cells exhibited enhanced dose response with 46%
and 58% increase in cell growth in 10 and 100 ng ml-' TGF-
a respectively (Figure 2a). As the concentration of exogenous
TGF-a was increased to 200 ng ml- , the response ofH226Br
-
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Figure 1 125I-labelled EGF binding assay. 1251-labelled EGF (0-
SOngml 1) in PBS was added to 5 x iO0 cells in 60mm Petri
dishes. Bound reactivity was determined after 2h incubation at
4°C. Non-specific binding was determined after addition of a 100-
fold excess ofunlabelled EGF and was always less than 3% ofthe
total binding. The binding of 1251-labelled EGF to A431 cells was
performed at the same time and analysed by Scatchard analysis.
0 and 0 represent binding of H226Br and NCI-H226 cells
respectively.
cell growth began to decrease to a level similar to that of
10 ng ml-' TGF-a, indicating the presence of an inhibitory
effect at this concentration. The inhibitory effect exerted by
200 ng ml-' TGF-a was more distinct as the H226Br cells in
the assay were reduced to 6000 (Figure 2b).
In addition, TGF-x-specific antibody inhibits H226Br
growth more effectively. The cells were cultured in different
concentrations of TGF-a-specific antibody. Both cell lines
showed a dose-dependent inhibitory effect (H226Br was
inhibited more than 50% at the highest titre) with inhibition
being reversed in the presence of 20 ng ml-' TGF-a (Figure
3a). The results indicate the importance of TGF-a in the
external autocrine loop for H226Br. The growth inhibition
induced by the TGF-a-specific antibody of the parental cells,
NCI-H226 (Figure 3b), is less distinct than that induced by
H226Br. The control cell, NCI-H460, with 1.4 x 104 EGF
binding sites per cell (unpublished data), were not affected by
the TGF-a-specific antibody at all concentrations tested.
Enhanced EGFR kinase activity in H226Br cells
The autophosphorylation activity of the EGFRs for both cell
lines was determined by immunoprecipitation of equal
amounts of cell lysates with extracellular domain-specific
EGFR monoclonal antibody R, followed by incubation with
[y-32P]ATP. EGFR autophosphorylation was shown to be
more active in H226Br, corresponding to enhanced ligand-
binding capacity for EGFR in H226Br (Figure 4).
To determine further the function of EGFRs, phosphor-
ylation was conducted with 35S-labelled EGFRs on intact
cells. After solubilisation with protease inhibitors, cell lysates
were immunoprecipitated with either phosphotyrosine anti-
body agarose conjugate or EGFR antibody and analysed by
SDS-PAGE. The basal phosphorylation level of EGFR was
not detected by phosphotyrosine-mediated immunoprecipita-
tion for both cell lines. After sti-mulation with 200 ng ml-'
EGF for 20 min, the phosphorylation signal and EGFR
could be detected by the electrophoretic mobility shift of
EGFR bands (Figure 5). Both NCI-H226 and H226Br cell
lysates are immunoactive to RI antibody and H226Br cells
were shown to have enhanced EGF-activated phosphoryla-
tion activity.
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Figure 2 Cell growth proliferation by TGF-a. (a) Cells (1 x 104
per well) and (b) H226Br cells (3- lOx 103 per well) were cultured
in 96-well microtitre plates in 5% FCS-supplemented RPMI-1640
medium overnight. The medium was changed to serum-free
medium overnight and different concentrations of TGF-a were
added. After 24h incubation at 37°C, 20p1 of MTT (5mgml-1)
was added to the cells for an additional 4h. Acid isopropanol was
added to dissolve the formazam crystal and the plate read at
570 nm wavelength while reading at 630 nm was used as a
reference. The percentage increase in MTT absorption for cells
incubated in different concentrations of TGF-a was compared
with that of cells incubated in serum-free medium alone. All
concentrations were tested in quadruplicates and the error bars
represent standard errors of three experiments (*P<0.05 and
*P<0.01, Student's t test, three experiments).
Increased EGFR transcript level in H226Br cells
Poly(A+)-enriched RNAs from both cell lines were separated
on formaldehyde-denatured agarose gel and blotted onto
GeneScreen membrane. The blot was hybridised with the
human EGFR ligand-binding domain-specific probe 64-1
(Schneider et al., 1990). Northern analysis indicated that
H226Br cells express more EGFR transcript than NCI-H226
as indicated by the densitometric difference of 10 kb EGFR
bands (Figure 6). The result demonstrated that the increased
EGFR level of H226Br is the result of enhanced transcrip-
tional activity of the EGFR gene during metastasis.
Expression and regulation of TGF-oa in NCI-H226 and H226Br
cells
Both cell lines were examined for the immunoactive TGF-a
level in the spent media using radioimmunoassay. The media
Figure 3 Cell growth affected by TGF-a-specific antibody. Cells
(1 x 104 per well) cultured in 96-well plates containing serum-free
RPMI-1640 were incubated with 0.5, 2.5 or 5ygml-' TGF-a-
specific antibody (Oncogene Science, Uniondale, NY, USA) with
or without human recombinant TGF-a (20ngml-1). After 24h
incubation at 37°C, the cells were stained with MTT and read at
590nm as in Figure 2. Cell cultures that were not treated with
TGF-a-specific antibody were counted as 100% controls. All
concentrations were tested in quadruplicate and the error bars
represent standard errors of three experiments (*P<0.05,
Student's t-test). Top; results for H226Br; bottom; NCI-H226.
Experiments using a non-specific monoclonal antibody with
similar isotype, MOPC-21, were carried out in parallel.
were collected and concentrated after 24 h incubation in
serum-free RPMI-1640. The accumulated immunoactive
TGF-a in NCI-H226 (174+ 13 pg per million cells) is higher
than that in H226Br (110 + 19 pg per million cells). As the
TGF-a message in NSCLC cannot be detected by Northern
analysis, cellular RNA was reverse transcribed and cDNA
amplified by polymerase chain reaction (PCR). Southern
analysis of the PCR products with TGF-a-specific probes
revealed that the basal TGF-cx transcript level in H226Br is
lower than that of NCI-H226, as determined by densitometry
(Figure 7).
Discussion
Human squamous cell carcinoma cells express high levels of
EGFR (Haeder et al., 1988; Kamata et al., 1986; Cowley et
al., 1984; Hendler et al., 1984). EGFR genes in primary
human glioblastoma and xenografted glioblastoma have been
shown to be amplified (Sugawa et al., 1990). Previously, we
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reported the isolation of a brain metastatic variant cell line
H226Br from human NSCLC cells NCI-H226. H226Br was
shown to have a different tumorigenic phenotype from the
parental cells, (Hwang et al., 1995). Lung cancer cells studied
in this work do not express EGF; instead TGF-ox was found
to be expressed as a natural ligand for EGFR (Roth, 1992).
The growth of the NSCLC cell line NCI-H226 was shown to
be modulated by a TGF-ax-mediated autocrine loop (Roth et
al., 1992).
A single low-affinity EGFR was found on NCI-H226 cells.
Both high-affinity and low-affinity EGFRs were found in
H226Br cells, which have greater EGF-binding capacity than
the parental cells, as indicated by dose-saturation binding
curves. The low-affinity EGFRs of H226Br have a
dissociation constant that is identical to that of the parental
cells. Both cell lines exhibited different kinase activities with
their immunoprecipitated EGFR. The immunoactive EGFR
of H226Br has enhanced autophosphorylation activity.
Furthermore, in intact H226Br cells, but not in NCI-H226
cells, the level of phosphorylated EGFR increased when
stimulated with EGF, as shown by phosphotyrosine anti-
body-mediated immunoprecipitation. Northern analysis with
an EGFR-specific probe indicated that the EGFR transcript
level is increased in H226Br, corresponding to increasing
protein translation and enhanced kinase activity. Up-
regulated TGF-oc-induced mitogenic activity was also
observed for H226Br. The optimal concentration of
mitogenic stimulation for H226 and H226Br by TGF-a is
10 and 100 ng ml-' respectively. When stimulated by TGF-oa
Cell type:
Antihodv
H226Br
R. M
at 10 and 100 ng ml-', the growth rate of H226Br is
increased by 46% and 58% respectively. On the other
hand, NCI-H226 cell growth is increased by 24% in
10 ng ml-' TGF-a and reduced to 11% when stimulated at
100 ng ml-'. In A431 epidermoid carcinoma cells with
increased EGFR, cell growth was inhibited by exogenous
nanomolar concentrations of TGF-a or EGF. The abundance
of low-affinity EGFRs which blocked cell growth in the G2
phase of the cell cycle, accounts for the lack of TGF-a
mitogenic stimulation in A431 cells (Rabiasz et al., 1992;
H226 NCI-H226
-EGFR (10 kb)
-5-Actin (1.3 kb)
NCI-H226
R. M
-200 kDa
-116
-92
Figure 4 Immune-complex EGFR kinase assay. Cell lysates of
H226Br and NCI-H226 in RIPA buffer were incubated with
EGFR antibody (RI) or non-specific antibody MOPC-21 (M).
Immune complexes were harvested by the addition of Staphylo-
coccus aureus and incubated with [y32P]ATP. Phosphorylated
EGFR was separated by SDS-PAGE (7.5%). The gels were
washed in 1 N sodium hydroxide at 80°C and dried before
exposure.
Cell type:
EGF: -
Antibody: P
H226Br
*+ +
R, M P Rft
Figure 6 Northern blot analysis of the EGFR gene. Oli-
go(dT)cellulose-purified RNA was separated on a 1.2%
formaldehyde-denatured agarose in MOPS buffer and transferred
to a GeneScreen membrane. For hybridization, the 32P-labelled
EGFR cDNA probe 64-1 was hybridised with the membrane (see
Materials and methods). The membrane was washed with 2 x SSC
and 1% SDS mixture at 65°C and exposed to radiographic film.
The blot was rehybridised with a 1.8kb BamHI fragment of the
human ,B-actin cDNA probe pHFl.
NCI-H226
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-200 kDa
-116
-92
-200 kDa
-1 8
-92
Figure 5 [35S]Methionine labelling and intact cell kinase assay of EGFR. The cells were labelled with [35S]methionine in
methionine-free medium and incubated at 37°C for 4h. The cells were (+) or were not (-) replaced with 200ngml-1 EGF in
RPMI-1640 for 20min at 37°C. The cell lysates were then incubated with EGFR antibody (R1), or antiphosphotyrosine agarose
conjugate (P) or non-specific antibody MOPC-21 (M). The pellets after Staphylococcus aureus precipitation were resolved by 7.5%
SDS-PAGE. The Enlighting-treated and dried gels were exposed to radiographic film.
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Figure 7 TGF-ax transcript expression as determined by RT-PCR
and Southern hybridisation. Cellular RNA was annealed with
random primers and reverse transcribed with M-MLV reverse
transcriptase. (a) Single-strand cDNA was amplified by PCR with
primers that amplify 297bp for TGF-a cDNA. The product was
resolved with 0.8% agarose gel, transferred to nitrocellulose and
hybridised with a digoxigenin-labelled TGF-a~cDNA probe that
was then hybridised with digoxigenin antibody-alkaline phospha-
tase conjugate, detected with chemiluminescent PPD and exposed
to radiographic film. The NSCLC cell lines NCI-H322 and N_-
H460 were used as positive and negative control respectively. (b)
Single-strand cDNA was amplified with fl-actin primers (420bp)
and hybridised with the digoxigenin-labelled fl-actin cDNA probe
pHFl. + and -, the presence and absence of M-MLV reverse-
transcriptase in the assay respectively.
Kamata et al., 1986; Gill et al., 1984; Kawamoto et al., 1983,
1984; MacLeod et al., 1986). On the other hand, the high
content of high-affinity EGFRs in H226Br cells (25% of the
total EGFRs compared with less than 1% in A431 cells) is
responsible for the growth stimulation by exogenous TGF-xc.
In all NSCLC cell lines studied, only a single type of low-
affinity EGFR was found.
Both cell lines express different TGF-a levels. In H226Br,
the immunoactive TGF-cx level is decreased compared with
NCI-H226, corresponding to their transcript difference.
Furthermore, the growth of H226Br is inhibited more
effectively by TGF-a-specific antibody, indicating that the
expressed TGF-ac in H226Br acts as an external autocrine
loop regulator in cell growth. The low TGF-a expression in
H226Br cells reflects the efficiency of the secreted growth
factor as a cell-to-cell communication signal, thereby
activating overexpressed EGFR and serving as an autocrine
stimulator more effectively than that in the parental cell line
NCI-H226. In the control cells, NCI-H322, which have
similar numbers of EGF binding sites (4.0 x 104 per cell for
NCI-H322 vs 4.5 x 104 per cell for NCI-H226) and high TGF-
a expression (Figure 7), a similar TGF-ac-mediated mitogenic
response was observed (26% increase for NCI-H322 vs 24%
for NCI-H226 in the presence of 10 ng TGF-a per ml of
media) (Figure 2a). In addition, TGF-x-specific antibody is
not an effective cell growth inhibitor in NCI-H226. The
excess TGF-a release attenuates EGFR down-regulation in
the parental cells, unlike the brain metastatic variant
(Derynck, 1992). The accumulated EGFRs serve as efficient
functional receptors for TGF-a, as occurs in liver-specific
metastasis (Fidler, 1995; Radinsky and Fidler, 1992). Recent
studies have shown that TGF-a and EGFR are located in
anterior pituitary and hypothalamus (Fan et al., 1995; Lazar
and Blum, 1992). Thus, it is interesting to discover that the
growth factor autocrine regulation that takes place in the
brain may account for tumorigenesis of squamous cells once
the blood brain-barrier is overcome. The growth of H226Br
has been shown to be regulated by insulin-like growth factor
I, which differs from the parental cells (Hwang et al., 1995).
Taken together, this work characterising growth factor
regulation during malignant transformation provides a
better understanding of the spectrum of molecular alteration
that occurs during metastasis of brain by human NSCLC
cells. Further investigation by blocking TGF-a-mediated
growth regulation ought to shed light on better containment
of metastasis formation
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